A Perspective on Personalized Therapies in Hypertrophic Cardiomyopathy.
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
23
08
2020
accepted:
23
11
2020
pubmed:
11
12
2020
medline:
15
12
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
A dominant mechanism of sudden cardiac death in the young is the progression of maladaptive responses to genes encoding proteins linked to hypertrophic cardiomyopathy. Most are mutant sarcomere proteins that trigger the progression by imposing a biophysical defect on the dynamics and levels of myofilament tension generation. We discuss approaches for personalized treatments that are indicated by recent advanced understanding of the progression.
Identifiants
pubmed: 33298734
pii: 00005344-202103000-00006
doi: 10.1097/FJC.0000000000000968
pmc: PMC7933064
mid: NIHMS1651354
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
317-322Subventions
Organisme : NHLBI NIH HHS
ID : P01 HL062426
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL112626
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128468
Pays : United States
Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Maron BJ, Maron MS, Maron BA, et al. Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy: JACC review topic of the week. J Am Coll Cardiol. 2019;73:1978–1986.
Neubauer S, Kolm P, Ho CY, et al. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry. J Am Coll Cardiol. 2019;74:2333–2345.
Force T, Bonow RO, Houser SR, et al. Research priorities in hypertrophic cardiomyopathy: report of a working group of the national heart, lung, and blood institute. Circulation. 2010;122:1130–1133.
Solaro CR, Solaro RJ. Implications of the complex biology and micro-environment of cardiac sarcomeres in the use of high affinity troponin antibodies as serum biomarkers for cardiac disorders. J Mol Cell Cardiol. 2020;143:145–158.
Alves ML, Dias FAL, Gaffin RD, et al. Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins. Circ Cardiovasc Genet. 2014;7:132–143.
Sheehan KA, Arteaga GM, Hinken AC, et al. Functional effects of a tropomyosin mutation linked to FHC contribute to maladaptation during acidosis. J Mol Cell Cardiol. 2011;50:442–450.
Lehman SJ, Tal-Grinspan L, Lynn ML, et al. Chronic calmodulin-kinase II activation drives disease progression in mutation-specific hypertrophic cardiomyopathy. Circulation. 2019;139:1517–1529.
Marszalek RJ, Solaro RJ, Wolska BM. Coronary arterial vasculature in the pathophysiology of hypertrophic cardiomyopathy. Pflugers Arch. 2019;471:769–780.
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Developed in collaboration with the American association for thoracic surgery, American society of echocardiography, American society of nuclear cardiology, heart failure society of America, heart rhythm society, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2011;58:e212–60.
Maron BJ. Hypertrophic cardiomyopathy in childhood. Pediatr Clin North America. 2004;51:1305–1346.
Vakrou S, Fukunaga R, Foster DB, et al. Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models. JCI Insight. 2018;3:e94493.
Coppini R, Ho CY, Ashley E, et al. Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. J Am Coll Cardiol. 2014;64:2589–2600.
Elliott PM. The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM. Cardiovasc Res. 2020;116:e175–e178.
Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759–769.
Ferrantini C, Pioner JM, Mazzoni L, et al. Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. Br J Pharmacol. 2018;175:2635–2652.
Lovelock JD, Monasky MM, Jeong EM, et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. 2012;110:841–850.
Huang L, Que L, Xi Y, et al. Myocardial mechanics parameters that predict left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a cardiovascular magnetic resonance feature tracking analysis. J Comput Assist Tomogr. 2020 [epub ahead of print].
Magrì D, Mastromarino V, Gallo G, et al. Risk stratification in hypertrophic cardiomyopathy. Insights from genetic analysis and cardiopulmonary exercise testing. J Clin Med. 2020;9:1636.
Parbhudayal RY, Harms HJ, Michels M, et al. Increased myocardial oxygen consumption precedes contractile dysfunction in hypertrophic cardiomyopathy caused by pathogenic TNNT2 gene variants. J Am Heart Assoc. 2020;9:e015316.
Rowin EJ, Sridharan A, Madias C, et al. Prediction and prevention of sudden death in young patients (<20 years) with hypertrophic cardiomyopathy. Am J Cardiol. 2020;128:75–83.
Maron BJ, Rowin EJ, Maron MS. Hypertrophic cardiomyopathy: is a 'cure' coming. Or is it already here? Am J Med. 2020;133:886–888.
Maron MS, Brush J, Rowin EJ, et al. Back to the future: predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring. Heart Rhythm. 2020:S1547 [epub ahead of print].
Aguiar Rosa S, Rocha Lopes L, Fiarresga A, et al. Coronary microvascular dysfunction in hypertrophic cardiomyopathy: pathophysiology, assessment, and clinical impact. Microcirculation. 2020:e12656.
Liu Y, Afzal J, Vakrou S, et al. Differences in microRNA-29 and pro-fibrotic gene expression in mouse and human hypertrophic cardiomyopathy. Front Cardiovasc Med. 2019;6:170.
Bos JM, Hebl VB, Oberg AL, et al. Marked up-regulation of ACE2 in hearts of patients with obstructive hypertrophic cardiomyopathy: implications for SARS-CoV-2-mediated COVID-19. Mayo Clinic Proc. 2020;95:1354–1368.
Shanmugam G, Wang D, Gounder SS, et al. Reductive stress causes pathological cardiac remodeling and diastolic dysfunction. Antioxid Redox Signal. 2020;32:1293–1312.
Patel BG, Wilder T, Solaro RJ. Novel control of cardiac myofilament response to calcium by S-glutathionylation at specific sites of myosin binding protein C. Front Physiol. 2013;4:336.
Wilder T, Ryba DM, Wieczorek DF, et al. N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2015;309:H1720–H1730.
Ryba DM, Warren CM, Karam CN, et al. Sphingosine-1-Phosphate receptor modulator, FTY720, improves diastolic dysfunction and partially reverses atrial remodeling in a Tm-E180G mouse model linked to hypertrophic cardiomyopathy. Circ Heart Fail. 2019;12:e005835.
Lomas DA, Belorgey D, Mallya M, et al. Molecular mousetraps and the serpinopathies. Biochem Soc Trans. 2005;33:321–330.
Gooptu B, Lomas DA. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem. 2009;78:147–176.
Asakura M, Kitakaze M. Global gene expression profiling in the failing myocardium. Circ J. 2009;73:1568–1576.
Sanchez-Navarro A, González-Soria I, Caldiño-Bohn R, et al. Integrative view of serpins in health and disease: the contribution of serpinA3. Am J Physiol Cell Physiol. 2020. [epub ahead of print].
Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol. 2004;483:79–93.
Groß S, Jahn C, Cushman S, et al. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to clinical implications. J Mol Cell Cardiol. 2020;144:47–53.
Thum T. SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure? Eur Heart J. 2020;41:1807–1809.
Tucker NR, Chaffin M, Bedi KC Jr, et al. Myocyte-specific upregulation of ACE2 in cardiovascular disease: implications for SARS-CoV-2-mediated myocarditis. Circulation. 2020;142:708–710.
Limongelli G, Crotti L. COVID-19 pandemia and inherited cardiomyopathies and channelopathies: a short term and long term perspective. Orphanet J Rare Dis. 2020;15:157.
Dolhnikoff M, Ferreira Ferranti J, de Almeida Monteiro RA, et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. Lancet Child Adolesc Health. 2020;4:790–794.
Fox SE, Li G, Akmatbekov A, et al. Unexpected features of cardiac pathology in COVID-19 infection. Circulation. 2020;142:1123–1125.
Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097–1100.
Sharma A, Garcia G Jr, Wang Y, et al. Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Rep Med. 2020;1:100052.
Flevaris P, Vaughan D. The role of plasminogen activator inhibitor type-1 in fibrosis. Semin Thromb Hemost. 2017;43:169–177.
Flevaris P, Khan SS, Eren M, et al. Plasminogen activator inhibitor type I controls cardiomyocyte transforming growth factor-β and cardiac fibrosis. Circulation. 2017;136:664–679.
Kalsheker NA. Alpha 1-antichymotrypsin. Int J Biochem Cel Biol. 1996;28:961–964.
Hooshdaran B, Kolpakov MA, Guo X, et al. Dual inhibition of cathepsin G and chymase reduces myocyte death and improves cardiac remodeling after myocardial ischemia reperfusion injury. Basic Res Cardiol. 2017;112:62.
Miller SA, Kolpakov MA, Guo X, et al. Intracardiac administration of neutrophil protease cathepsin G activates noncanonical inflammasome pathway and promotes inflammation and pathological remodeling in non-injured heart. J Mol Cell Cardiol. 2019;134:29–39.
Li Z, Solomonidis EG, Meloni M, et al. Single-cell transcriptome analyses reveal novel targets modulating cardiac neovascularization by resident endothelial cells following myocardial infarction. Eur Heart J. 2019;40:2507–2520.
See K, Tan WLW, Lim EH, et al. Single cardiomyocyte nuclear transcriptomes reveal a lincRNA-regulated de-differentiation and cell cycle stress-response in vivo. Nat Commun. 2017;8:225.
Tucker NR, Chaffin M, Fleming SJ, et al. Transcriptional and cellular diversity of the human heart. Circulation. 2020;142:466–484.
van Heesch S, Witte F, Schneider-Lunitz V, et al. The translational landscape of the human heart. Cell. 2019;178:242–260.e29.
Sanz E, Yang L, Su T, et al. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc Natl Acad Sci U S A. 2009;106:13939–13944.
Cleuren ACA, van der Ent MA, Jiang H, et al. The in vivo endothelial cell translatome is highly heterogeneous across vascular beds. Proc Natl Acad Sci U S A. 2019;116:23618–23624.
Walsh D, Mathews MB, Mohr I. Tinkering with translation: protein synthesis in virus-infected cells. Cold Spring Harb Perspect Biol. 2013;5:a012351.